Surgical Science Sweden SUS.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker SUS.ST. It has been listed since 19 June 2017. In the fiscal year to 31 December 2025, it reported revenue of SEK 992.3m and net income of SEK 66.8m. At that date it held total assets of SEK 4.69bn and shareholders' equity of SEK 4.27bn.

Surgical Science Sweden AB engages in the development of simulators for laparoscopic medical training. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-06-19. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Tom EnglundChief Executive Officer
• Ms. Anna AhlbergChief Financial Officer
• Mr. Ran BronsteinPresident - Research and Development
• Mr. Boaz TalChief Operating Officer
• Mr. Doron ZilbermanExecutive Vice President of International Sales
• Ms. Inbal MazorExecutive Vice President Products and Marketing
• Mr. Niclas OlssonExecutive Vice President - Industry/OEM
• Mr. Anders LarssonChief Technology Officer
• Mr. Jan BengtssonDirector, since 2005
• Mr. Gisli HennermarkDirector, since 2015SEK 5.2m
• Mr. Thomas EklundIndependent Director
• Mr. Henrik FalconerIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.